These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 31174726

  • 1. The prevalence of pulmonary hypertension in Cavalier King Charles spaniels compared with other breeds with myxomatous mitral valve disease.
    Sudunagunta S, Green D, Christley R, Dukes-McEwan J.
    J Vet Cardiol; 2019 Jun; 23():21-31. PubMed ID: 31174726
    [Abstract] [Full Text] [Related]

  • 2. Heart rate, heart rate variability, and arrhythmias in dogs with myxomatous mitral valve disease.
    Rasmussen CE, Falk T, Zois NE, Moesgaard SG, Häggström J, Pedersen HD, Ablad B, Nilsen HY, Olsen LH.
    J Vet Intern Med; 2012 Jun; 26(1):76-84. PubMed ID: 22151356
    [Abstract] [Full Text] [Related]

  • 3. Serotonin concentrations in platelets, plasma, mitral valve leaflet, and left ventricular myocardial tissue in dogs with myxomatous mitral valve disease.
    Cremer SE, Singletary GE, Olsen LH, Wallace K, Häggström J, Ljungvall I, Höglund K, Reynolds CA, Pizzinat N, Oyama MA.
    J Vet Intern Med; 2014 Jun; 28(5):1534-40. PubMed ID: 25146933
    [Abstract] [Full Text] [Related]

  • 4. Urine 5-hydroxyindoleacetic acid in Cavalier King Charles spaniels with preclinical myxomatous mitral valve disease.
    Christiansen LB, Cremer SE, Helander A, Madsen T, Reimann MJ, Møller JE, Höglund K, Ljungvall I, Häggström J, Olsen LH.
    Vet J; 2019 Aug; 250():36-43. PubMed ID: 31383418
    [Abstract] [Full Text] [Related]

  • 5. Relationship between syringomyelia and myxomatous mitral valve disease in Cavalier King Charles spaniels.
    Bach MBT, Stougaard CL, Thøfner MS, Reimann MJ, Westrup U, Koch J, Fredholm M, Martinussen T, Berendt M, Olsen LH.
    J Vet Intern Med; 2024 Aug; 38(2):904-912. PubMed ID: 38391152
    [Abstract] [Full Text] [Related]

  • 6. Use of physical examination, electrocardiography, radiography, and biomarkers to predict echocardiographic stage B2 myxomatous mitral valve disease in preclinical Cavalier King Charles Spaniels.
    Wesselowski S, Gordon SG, Fries R, Saunders AB, Sykes KT, Vitt J, Boutet B, Häggström J, Kadotani S, Stack J, Barnett BG.
    J Vet Cardiol; 2023 Dec; 50():1-16. PubMed ID: 37913604
    [Abstract] [Full Text] [Related]

  • 7. Circulating cytokine concentrations in dogs with different degrees of myxomatous mitral valve disease.
    Zois NE, Moesgaard SG, Kjelgaard-Hansen M, Rasmussen CE, Falk T, Fossing C, Häggström J, Pedersen HD, Olsen LH.
    Vet J; 2012 Apr; 192(1):106-11. PubMed ID: 21696985
    [Abstract] [Full Text] [Related]

  • 8. Genetic Variants at the Nebulette Locus Are Associated with Myxomatous Mitral Valve Disease Severity in Cavalier King Charles Spaniels.
    Mead SE, Beijerink NJ, O'Brien M, Wade CM.
    Genes (Basel); 2022 Dec 05; 13(12):. PubMed ID: 36553559
    [Abstract] [Full Text] [Related]

  • 9. Tricuspid annular plane systolic excursion in dogs with myxomatous mitral valve disease with and without pulmonary hypertension.
    Poser H, Berlanda M, Monacolli M, Contiero B, Coltro A, Guglielmini C.
    J Vet Cardiol; 2017 Jun 05; 19(3):228-239. PubMed ID: 28579307
    [Abstract] [Full Text] [Related]

  • 10. Comparison of cellular changes in Cavalier King Charles spaniel and mixed breed dogs with myxomatous mitral valve disease.
    Lu CC, Liu MM, Culshaw G, French A, Corcoran B.
    J Vet Cardiol; 2016 Jun 05; 18(2):100-9. PubMed ID: 26860643
    [Abstract] [Full Text] [Related]

  • 11. Mitral Regurgitation Severity and Left Ventricular Systolic Dimension Predict Survival in Young Cavalier King Charles Spaniels.
    Reimann MJ, Møller JE, Häggström J, Martinussen T, Zatrazemi SSC, Svanholm L, Nielsen LBM, Pedersen HD, Olsen LH.
    J Vet Intern Med; 2017 Jul 05; 31(4):1008-1016. PubMed ID: 28573754
    [Abstract] [Full Text] [Related]

  • 12. Prospective pilot study on the predictive significance of plasma miR-30b-5p through the study of echocardiographic modifications in Cavalier King Charles Spaniels affected by different stages of myxomatous mitral valve disease: The PRIME study.
    Ghilardi S, Lecchi C, Bagardi M, Romito G, Colombo FM, Polli M, Franco C, Brambilla PG.
    PLoS One; 2022 Jul 05; 17(12):e0274724. PubMed ID: 36574372
    [Abstract] [Full Text] [Related]

  • 13. Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration.
    Reimann MJ, Häggström J, Møller JE, Lykkesfeldt J, Falk T, Olsen LH.
    J Vet Intern Med; 2017 Mar 05; 31(2):295-302. PubMed ID: 28132441
    [Abstract] [Full Text] [Related]

  • 14. Influence of Morphometry on Echocardiographic Measurements in Cavalier King Charles Spaniels: An Inverse Probability Weighting Analysis.
    Bagardi M, Ghilardi S, Locatelli C, Bionda A, Polli M, Bussadori CM, Colombo FM, Pazzagli L, Brambilla PG.
    Vet Sci; 2021 Sep 23; 8(10):. PubMed ID: 34679035
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of genes associated with human myxomatous mitral valve disease in dogs with familial myxomatous mitral valve degeneration.
    Meurs KM, Friedenberg SG, Williams B, Keene BW, Atkins CE, Adin D, Aona B, DeFrancesco T, Tou S, Mackay T.
    Vet J; 2018 Feb 23; 232():16-19. PubMed ID: 29428085
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Echocardiographic parameters for the assessment of congestive heart failure in dogs with myxomatous mitral valve disease and moderate to severe mitral regurgitation.
    Morgan KRS, Monteith G, Raheb S, Colpitts M, Fonfara S.
    Vet J; 2020 Sep 23; 263():105518. PubMed ID: 32928487
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.